Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: AJR Am J Roentgenol. 2020 Oct 14;217(3):720–729. doi: 10.2214/AJR.20.24509

Fig. 4—

Fig. 4—

64-year-old man with biopsy-proven Gleason 4 + 5 prostate cancer in left base and serum PSA value of 11.1 ng/mL and equivocal conventional staging with 1.3 cm (borderline enlarged) left internal iliac lymph node (same patient as in Fig. 3) after 6 weeks of androgen deprivation therapy and decrease in serum PSA value from 11.1 to 0.3 ng/mL. A–D, Fused 18F-fluciclovine PET/MR images show decreased activity (arrow, A and B) within primary prostate lesion (A) and left internal iliac lymph node (B), and resolution of activity in additional previously identified suspicious pelvic lymph nodes (C and D).